Literature DB >> 10075867

Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.

F Gomez1, P Ruiz, F Briceño, C Rivera, R Lopez.   

Abstract

Macrophage Fcgamma receptors have an important role in host defense and the pathophysiology of immune mediated disorders. Alteration of splenic macrophage Fcgamma receptors expression predisposes to severe infection. Inhibition or blockade of splenic macrophage Fcgamma receptors is one of the mechanisms by which immune cytopenias improve. Dopaminergic drugs have clinically significant regulatory functions on the immune response. Using an experimental model in the guinea pig we assessed the effect of commonly used dopaminergic drugs on the expression of macrophage Fcgamma receptors. Three dopa-antagonists, bromocryptine, leuprolide, and pergolide, and seven dopa-antagonists, chlorpromazine, SCH 23390, metochlopramide, sulpiride, veralipride, alizapride, and cisapride, were studied. Following guinea pig treatment with dopaminergic drugs, the clearance of IgG-sensitized RBCs in vivo, the in vitro binding of IgG-sensitized RBCs by isolated splenic macrophages and flow cytometry with monoclonal antibodies were performed. Treatment with dopa-agonists enhanced the clearance of IgG-sensitized RBCs, the in vitro binding of IgG-sensitized RBCs by isolated splenic macrophages, and the cell surface expression of both macrophage Fcgamma receptors, and vice versa, dopa-antagonists impaired macrophage Fcgamma receptors expression. Macrophage FcgammaR1,2 was more sensitive than FcgammaR2 to such dopaminergic effect. These alterations of macrophage Fcgamma receptors expression are mediated by both D1 and D2 dopamine receptors, with a major participation of D2 receptors. Dopaminergic drugs alter the clearance of IgG-coated cells by an effect at the expression of splenic macrophage Fcgamma receptors. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075867     DOI: 10.1006/clim.1998.4665

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  8 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse.

Authors:  Peter J Gaskill; Tina M Calderon; Aimée J Luers; Eliseo A Eugenin; Jonathan A Javitch; Joan W Berman
Journal:  Am J Pathol       Date:  2009-08-06       Impact factor: 4.307

3.  Enhancement of splenic-macrophage Fcgamma receptor expression by treatment with estrogens.

Authors:  F Gomez; P Ruiz; J A Bernal; M Escobar; A Garcia-Egido; J J Lopez-Saez
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  Effects of androgen treatment on expression of macrophage Fcgamma receptors.

Authors:  F Gomez; P Ruiz; R Lopez; C Rivera; S Romero; J A Bernal
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

Review 5.  Dopaminergic Regulation of Innate Immunity: a Review.

Authors:  Monica Pinoli; Franca Marino; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2017-06-03       Impact factor: 4.147

Review 6.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

Review 7.  Immunomodulatory Effects Mediated by Dopamine.

Authors:  Rodrigo Arreola; Samantha Alvarez-Herrera; Gilberto Pérez-Sánchez; Enrique Becerril-Villanueva; Carlos Cruz-Fuentes; Enrique Octavio Flores-Gutierrez; María Eugenia Garcés-Alvarez; Dora Luz de la Cruz-Aguilera; Emilio Medina-Rivero; Gabriela Hurtado-Alvarado; Saray Quintero-Fabián; Lenin Pavón
Journal:  J Immunol Res       Date:  2016-10-04       Impact factor: 4.818

Review 8.  The role of dopaminergic immune cell signalling in poststroke inflammation.

Authors:  Daniela Talhada; Monika Rabenstein; Karsten Ruscher
Journal:  Ther Adv Neurol Disord       Date:  2018-05-10       Impact factor: 6.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.